The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

Methods of CH bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp.sup.3 CH bond and a fluorinating agent and converting the sp.sup.3 CH bond to a CF bond in the presence of the non-heme manganese catalyst or a derivative thereof.

Methods of CH bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp.sup.3 CH bond and a fluorinating agent and converting the sp.sup.3 CH bond to a CF bond in the presence of the non-heme manganese catalyst or a derivative thereof.

The present disclosure provides methods for making quinolinyldiamine products from quinolinyl starting materials. In addition, the quinolinyldiamines can be used as ligands or ligand precursors for catalysts, e.g. for use in olefin polymerization.

The present disclosure provides methods for making quinolinyldiamine products from quinolinyl starting materials. In addition, the quinolinyldiamines can be used as ligands or ligand precursors for catalysts, e.g. for use in olefin polymerization.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

A process of forming compounds of formula I ##STR00001##
comprising the steps of addition of an amino compound H.sub.2NR to a compound of formula (II) ##STR00002##
followed by cyclization, isomerization and hydrolysis.

A process of forming compounds of formula I ##STR00001##
comprising the steps of addition of an amino compound H.sub.2NR to a compound of formula (II) ##STR00002##
followed by cyclization, isomerization and hydrolysis.